Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requirements for Evolent review/prior authorization of oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care members; applies to participating providers dispensing/administering these drugs via pharmacy or medical settings.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen and supporting clinical indication to Evolent via their web portal or phone.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+HCPCS/CPT/J-codes listed requiring review
    Medical & Pharmacybenefit settings referenced
    5/1/2026effective date
    Evolent portal/phonesubmission route

    Coverage Criteria

    Prior Authorization / Review Requirement

    Covered when ALL of the following are met

    Evolent review required: The listed oncology medications and supportive agents (as identified by the HCPCS/J/Q code lists and oral agent listings) must be submitted to Evolent for review prior to being dispensed at a pharmacy or administered in a physician's office, outpatient hospital, or ambulatory setting for participating providers.

    Includes drugs billed to either the medical or pharmacy benefit as indicated in the code lists; clinical trials may be submitted for review. Requests can be submitted via Evolent web portal or phone; non‑participating providers submit to the plan via fax.

    The following requests are out of scope and should NOT be submitted to Evolent: antibiotics; bone marrow, stem cell transplants and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests (such as infusion pumps); genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    Coding (HCPCS / J-codes / Q-codes)

    Listed HCPCS/J-codes (sample from list)mixed
    C9293GLUCARPIDASE
    J0894
    J0185DECITABINE INJ / APREPITANT INJ
    J0896
    J0207LUSPATERCEPT-AAMT / AMIFOSTINE INJ
    J0208DENOSUMAB PROLIA / SODIUM THIOSULFATE
    J0594BUSULFAN INJ
    J1010
    J0641LEVOLEUCOVORIN INJ
    J0642LEVOLEUCOVORIN INJ
    Additional HCPCS/J-codesmixed
    J9034BENDAMUSTINE (RAPID INFUSION BENDEKA)
    J9045CARBOPLATIN INJ
    J9171DOCETAXEL INJ
    J9200FLOXURIDINE INJ
    J9271PEMBROLIZUMAB
    Q-codes / biosimilar product codesmixed
    Q5101FILGRASTIM-SNDZ
    Q5110PEGFILGRASTIM-JMDB
    Q5116RITUXIMAB-ABBS
    Oral oncology agents / J8999 groupmixed
    J8999ORAL ONCOLOGY AGENTS (many specific drugs listed under J8999)
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL
    inv-07: Effective date
    Effective date5/1/2026
    Applies toWellcare by Fidelis Care additions
    ScopeEffective date applies to oral oncology (J8999) group additions listed in the policy

    Provider Actions and Submission Requirements

    Prior Authorization

    Evolent review required before dispensing/administration

    Specified oncology medications and supportive agents listed by HCPCS/J/Q-code must be submitted to Evolent for review prior to being dispensed at a pharmacy or administered in a physician's office, outpatient hospital, or ambulatory setting for participating providers.

    • Applies to members of all ages.
    • Drugs listed in the HCPCS/J/Q code lists (see coding section) will be available via medical or pharmacy benefit as indicated.
    Prior Authorization

    Pharmacy‑benefit oral oncology agents require Evolent review

    Oral oncology agents—many billed under J8999 or specific oral J-codes—require submission to Evolent for review and will be available via the pharmacy benefit only as listed.

    • Examples include J8999 group oral targeted agents (e.g., abemaciclib, abiraterone, alectinib) and specific oral J-codes such as J7520, J7527, J8501.
    • Submit these oral agents to Evolent regardless of intended benefit routing.

    Background

    This policy centralizes prior authorization and clinical review of oncology medications and supportive agents through Evolent to establish medical necessity and route benefit (medical vs pharmacy). Participating providers must submit oncology medication requests and the complete oncology regimen to Evolent for review prior to dispensing or administration; omissions in regimen submission may result in a denial.

    Definitions

    inv-15: Participating provider
    DefinitionA provider contracted with the plan who must submit oncology medication requests to Evolent for review prior to dispensing or administration.
    Required actionParticipating providers must submit the entire oncology regimen and supporting clinical indication to Evolent via their web portal or phone prior to dispensing/administration.
    Submission routesEvolent web portal (my.newcenturyhealth.com) or phone 1-888-999-7713, option 1; non-participating providers submit to the plan via fax.
    Consequence of noncomplianceFailure to submit the entire oncology regimen or to obtain Evolent review prior to dispensing/administration may result in a denial.

    Initial Therapy Criteria

    Initial review

    Initial authorization requirement

    Submission: Initial and subsequent requests for the listed oncology agents and supportive drugs must be submitted to Evolent for review to establish a medically accepted indication and to determine benefit routing (medical vs pharmacy).

    Applies to members of all ages for participating providers; submit the entire oncology regimen to Evolent—omissions may result in denial.

    Step Therapy / Preferred Agents

    Preferred agentBenefit setting / notes
    Erythropoiesis‑stimulating agents — Retacrit (medical benefit)Medical benefit — Retacrit preferred; if unavailable due to shortage: Epogen. Providers must still submit to Evolent for review.
    Erythropoiesis‑stimulating agents — Procrit (pharmacy benefit)Pharmacy benefit — Procrit preferred. Providers must still submit to Evolent for review.
    Trastuzumab biosimilar — Trazimera (medical benefit)Medical benefit — Trazimera preferred. Providers must still submit to Evolent for review.
    Trastuzumab products (pharmacy benefit) — Herceptin; Herceptin Hylecta; Herzuma; Kanjinti; Ogivri; Ontruzant; TrazimeraPharmacy benefit — listed trastuzumab products preferred; providers must still submit to Evolent for review.
    Bevacizumab biosimilars — Mvasi; Zirabev (medical benefit)Medical benefit — Mvasi and Zirabev preferred; providers must still submit to Evolent for review.
    Bevacizumab products (pharmacy benefit) — Avastin; Mvasi; ZirabevPharmacy benefit — listed bevacizumab products preferred; providers must still submit to Evolent for review.
    Hematopoietic agent — Zarxio (medical & pharmacy benefit)Medical & pharmacy benefit — Zarxio preferred; providers must still submit to Evolent for review.

    Site of Care

    Note

    Review required regardless of administration setting

    Drugs on the list require Evolent review regardless of site of care when administered in a physician office, outpatient hospital, ambulatory setting, or dispensed at a pharmacy.

    • The review requirement applies to members of all ages and to participating providers.

    Biosimilar Preferences

    Billing Rule

    Epogen/Procrit — preferred biosimilar listed; submit for review

    Retacrit is listed as the preferred erythropoiesis-stimulating agent (medical benefit) with Procrit noted for pharmacy benefit; providers must still submit requests for these agents to Evolent for review.

    • If Retacrit is unavailable due to shortage, Epogen is noted as an alternative for the medical benefit.
    Billing Rule

    Herceptin and trastuzumab biosimilars — preferred listing; submission required

    Trazimera is listed as a preferred trastuzumab product (medical benefit) and multiple trastuzumab products are listed for pharmacy benefit, but providers must still submit trastuzumab requests to Evolent for review.

    • Pharmacy benefit trastuzumab options include Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, and Trazimera.

    Revision History

    2026-05-01policy_effective_dateLatest

    Policy additions for Wellcare by Fidelis Care (including oral J8999 listings) become effective for this plan on 5/1/2026.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen and supporting clinical indication to Evolent via their web portal or phone.
    SourceLink
    On This Page
    Coverage CriteriaCoding (HCPCS / J-codes / Q-codes)Provider Actions and Submission RequirementsBackgroundDefinitionsInitial Therapy CriteriaStep Therapy / Preferred AgentsSite of CareBiosimilar PreferencesRevision History
    Step Therapy

    Preferred biosimilars must still be submitted to Evolent

    Preferred biosimilar agents are identified (e.g., Retacrit for ESAs; Trazimera for trastuzumab; Mvasi/Zirabev for bevacizumab) and should be submitted to Evolent for review; listing as preferred does not remove the requirement to submit.

    • Providers must still send preferred biosimilars to Evolent for review prior to dispensing or administration.
    • Both medical- and pharmacy-benefit preferred biosimilars are listed in the policy.
    Documentation Required

    How to submit oncology regimen to Evolent

    Submit the entire oncology regimen and the supporting clinical indication to Evolent via the web portal (my.newcenturyhealth.com) or by phone (1-888-999-7713, option 1). Non‑participating providers must submit requests to the plan via fax (1-844-235-5090).

    • Include the complete regimen—omissions may lead to denials.
    • Web portal and phone are the routes for participating providers; fax is for non‑participating providers.
    Denial Risk

    Submit entire regimen or risk denial

    Failure to submit the entire oncology regimen to Evolent may result in a denial of the request.

    • The policy repeatedly instructs: “Please submit the entire oncology regimen to Evolent, regardless of prior authorization requirement. Any omissions may result in a denial.”
    Denial Risk

    Prior review is required for participating providers

    Requests not reviewed by Evolent for participating providers prior to dispensing or administration can trigger denials; participating providers must obtain Evolent review before dispensing/administration.

    • Participating providers are required to submit requests to Evolent before providing the drug in any outpatient setting or via pharmacy.
    • Clinical trials may also be sent to Evolent for review.